AACR Announces 2025 Breast Cancer Research Award Recipients Ahead of SABCS 2025
@theaacr.bsky.social
@sabcs.bsky.social
@stolaney1.bsky.social
oncodaily.com/industry/aac...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #AACR #BreastCancer #SABCS #SABCS2025
Thank you so mcuh @stoverlab.bsky.social for the phenomenal keynote lecture-- you have built an incredible translational research infrastructure and team!
It was wonderful to have you back in Boston!
@dfcibreastonc.bsky.social
Don't miss this recent review outlining practical treatment strategies and novel therapies in the PI3K/AKT/mTOR pathway in HR+/HER2- advanced #BreastCancer
🔓 pubmed.ncbi.nlm.nih.gov/39674130/
@antgiordanomd.bsky.social @drtimothyerick.bsky.social @stolaney1.bsky.social @drsarahsammons.bsky.social
Congratulations all!! @stolaney1.bsky.social @lymphomadoc.bsky.social @ryannipp.bsky.social and more! #FASCO
very important (but negative) trial on cdk46i in mTNBC. huge shout-out to @stolaney1.bsky.social and Shom Goel for conducting this trial👍 @oncoalert.bsky.social #bcsm
Don't miss this recent Current Oncology Reports review on #AntibodyDrugConjugates in #BreastCancer: The Road Towards Biologically-Informed Selection and Sequencing pubmed.ncbi.nlm.nih.gov/39786525/
@ptarantinomd.bsky.social @ilanaschlam.bsky.social @stolaney1.bsky.social #AnaGarridoCastro
Dr. Paolo Tarantino (@ptarantinomd.bsky.social)
and Dr. Sara Tolaney (@stolaney1.bsky.social) discuss efforts to create consensus based #BreastCancer Treatment Guidelines, which are meant to encourage uniform, evidence-based practice. Read here ⬇️
physicianresources.dana-farber.org/symposium/br...
Join Dr. Sara Tolaney (@stolaney1.bsky.social) tomorrow at #SABCS24 for an insightful #CareerDevelopment session, focused on early funding for research. Dr. Tolaney will discuss the importance of having foundation and community program support.
🗓️ Dec 10th
⏰12:00–1:45 pm CST (1:00 pm EST)
📍Rm 221ABC
Dr. Sara Tolaney (@stolaney1.bsky.social) will moderate the #SABCS24 poster spotlight session 3 on novel therapeutics in #BreastCancer on Wed Dec 11th – don’t miss it!
🗓️ Wednesday, December 11th
⏰ 7:00 – 8:30 am CST (8:00 – 9:30 am EST)
📍 Stars at Night 1-2
Dr. Sara Tolaney (@stolaney1.bsky.social) offered great tips and strategies for obtaining research funding from foundations and community programs in the #SABCS24 Career Development Session. Biggest take away: Start early!
@danafarber.bsky.social
Thank you all for stepping by and chatting with me yesterday. Thanks to @dfcibreastonc.bsky.social , my mentor @stolaney1.bsky.social , and all the co-authors for this great opportunity 😊
#SABCS2024 @sabcs.bsky.social
Meet Dr. Stefania Morganti, an Advanced Fellow at the Breast Oncology Center at @danafarber.bsky.social. Dr. Morganti earned her MD at the University of Pavia and specialized in medical oncology. Her research is aimed at developing patient-centered approaches to advance #BreastCancer treatment.
Check out this recent review on the role of #AntibodyDrugConjugates in the treatment of patients with #BreastCancerBrainMetastases.
pubmed.ncbi.nlm.nih.gov/39529890/
#StaceyPan @drsarahsammons.bsky.social @nlinmd.bsky.social @stolaney1.bsky.social @ilanaschlam.bsky.social @ptarantinomd.bsky.social
Check out the #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (November 25th- December 1st, 2024). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch
Can we bring 2L PFS closer to 12 months post 1L CDK4/6i? More work needed to improve biomarkers for selection of optimal 2L therapeutic option. #ESMOASIA24
Make sure to follow @dfcibreastonc.bsky.social for updates on the latest research efforts by DFCI BOC and for periodic research digest with recent news in breast oncology! @stolaney1.bsky.social
Dr. Abirami Natarajan and Dr. Sara Tolaney (@stolaney1.bsky.social) discuss adjuvant #ribociclib in this
Annals of Oncology editorial.
👀 check it out here:
sciencedirect.com/science/arti...
Out in @TheLancetOncol
De-escalated neoadjuvant CT with trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer
PCR rate 66.3% vs. 57.6% in the nab-paclitaxel group vs. in the docetaxel + carbo group
@oncoalert.bsky.social
www.thelancet.com/journals/lan...
We are looking forward to this year's San Antonio Breast Cancer Symposium which starts on December 10. Take a look at the full program for this important meeting featuring the latest research on breast cancer. sabcs.org/FullProgram #SABCS24 #breastcancer
Link for more info & to access FDA-ASCO Fellows’ Day Workshop application is here: asco.smapply.org/prog/Februar....
Apply by 12/4/24. Hope to see some of you in person or on Zoom for a day of #regulatory science #MedEd, #OncSky! 😃
#MedSky #healthpolicy #mentorship #OncoAlert
Grade 1-2 treatment-related irAEs in the first cycle of therapy were associated with longer overall survival compared to no irAEs from checkpoint inhibitors. #survonc #supponc
doi.org/10.1093/jnci...
Looking forward to #SABCS24 - there is a lot of important research being presented, some to highlight:
🔑 Biomarker analysis of KN522
🔑 EMBER-3
🔑 MARGOT
🔑 SONIA
🔑 EUROPA
🔑 SOLTI VALENTINE
🔑 GeparDouze
We are going to be bringing #SABCS24 updates to #BlueSky too starting Dec 10th!
Many great colleagues on here including some amazing advocates.
@itsnotpink.bsky.social
@janicetnbcmets.bsky.social
@oncbrothers.bsky.social
@hoperugo.bsky.social
....and others!
@sabcs.bsky.social
#bcsm